Cheever MA, Higano CS. PROVENGE (Sipuleucel -T) in prostate cancer: the first FDA -approved therapeutic cancer vaccine. Clin Cancer Res 17 , 3520 -3527 (2011). Colombetti S, Levy F, Chapatte L. IL -7 adjuvant treatment enhances long -term tumor -antigen -specific CD8+ T-cell responses after immunization with recombinant lentivector. Blood 113, 6629 –6637 (2009). Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228 -47, 2009 FDA.gov.